LY3410738

Phase 1Small molecule

Eli Lilly

LY3410738 is one of 65 small molecule programs targeting Acute Myeloid Leukemia (AML). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid Leukemia (AML)Active, not recruiting

CholangiocarcinomaActive, not recruiting

Acute Myeloid Leukemia (AML)Phase 1

Active, not recruiting

CholangiocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

19 2

Zykadia

Colcrys

Camptosar

Rocaltrol

Ixempra

Wellcovorin

GGlaxo Dba Glaxosmithkline

Approved

—8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 9

Tecentriq

Roche

Phase 3

3 10

Cotellic

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Cholangiocarcinoma

NCT04521686

Phase 1Active, not recruiting

Acute Myeloid Leukemia (AML)

NCT04603001

Clinical

Trials by Indication[1]

Adult2 trials

A Study of LY3410738 in Healthy Adult Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06181045·42 enrolled

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06181084·60 enrolled

CAR1 trial

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT05205447·27 enrolled

Cholangiocarcinoma1 trial

A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT04521686·200 enrolled

Acute Myeloid Leukemia (AML)1 trial

A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT04603001·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LY3410738. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3410738 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3410738. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY3410738

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Adult2 trials

CAR1 trial

Cholangiocarcinoma1 trial

Acute Myeloid Leukemia (AML)1 trial

References

Drug Info

Quick Facts

Related News